Regular follow-up appointments during the initial months allow for timely intervention if problems arise
How to Communicate This to Your Patients Changes like these can be frustrating for patients, especially when theyve found a solution that works for them
Notably, there were several first-time approvals including a once-weekly basal insulin for type 2 diabetes, treatments for rare diseases such as Hunter syndrome, Menkes disease and cholestatic pruritus associated with primary biliary cholangitis, as well as a new gene therapy for an inherited immune deficiency
Sources: OASIS 4 trial (NEJM 2025), FDA approval documentation (Dec 2025), Wegovy prescribing information (Novo Nordisk 2025)
Lincoff AM, Brown-Frandsen K, Colhoun HM, Deanfield J, Emerson SS, Esbjerg S, Hardt-Lindberg S, Hovingh GK, Kahn SE, Kushner RF, Lingvay I, Oral TK, Michelsen MM, Plutzky J, Tornoe CW, Ryan DH